Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients
Open Access
- 1 June 2008
- journal article
- Published by Elsevier in Journal of Lipid Research
- Vol. 49 (6), 1344-1352
- https://doi.org/10.1194/jlr.p800003-jlr200
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- HDL-inflammatory index correlates with poor outcome in hemodialysis patientsKidney International, 2007
- Effect of Torcetrapib on Carotid Atherosclerosis in Familial HypercholesterolemiaNew England Journal of Medicine, 2007
- Effect of Torcetrapib on the Progression of Coronary AtherosclerosisNew England Journal of Medicine, 2007
- Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factorsJournal of Applied Physiology, 2006
- Molecular regulation of HDL metabolism and function: implications for novel therapiesJournal of Clinical Investigation, 2006
- When pouring water on the fire makes it burn brighterCell Metabolism, 2005
- Apolipoprotein A-I Deficiency Results in Markedly Increased Atherosclerosis in Mice Lacking the LDL ReceptorArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- The antiatherogenic role of high-density lipoprotein cholesterolThe American Journal of Cardiology, 1998
- High-Density Lipoprotein — The Clinical Implications of Recent StudiesNew England Journal of Medicine, 1989